Oncology Institute (NASDAQ:TOI) Stock Price Down 6.9% – Time to Sell?

The Oncology Institute, Inc. (NASDAQ:TOI)’s share price fell 6.9% during mid-day trading on Thursday . The stock traded as low as $0.88 and last traded at $0.89. 259,349 shares were traded during trading, a decline of 69% from the average session volume of 848,664 shares. The stock had previously closed at $0.96.

Oncology Institute Trading Down 0.4 %

The stock has a market capitalization of $67.24 million, a PE ratio of -1.14 and a beta of 0.37. The firm has a 50-day moving average price of $0.58 and a 200-day moving average price of $0.40. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 5.91.

Insider Activity

In other news, Director Brad Hively acquired 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was bought at an average price of $0.17 per share, with a total value of $42,500.00. Following the acquisition, the director now owns 616,753 shares in the company, valued at $104,848.01. The trade was a 68.17 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On Oncology Institute

Several large investors have recently added to or reduced their stakes in TOI. HighTower Advisors LLC increased its holdings in Oncology Institute by 190.8% in the 3rd quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock worth $27,000 after acquiring an additional 53,382 shares during the last quarter. Jane Street Group LLC increased its holdings in Oncology Institute by 613.6% in the 4th quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock worth $39,000 after acquiring an additional 109,769 shares during the last quarter. Virtu Financial LLC purchased a new stake in Oncology Institute in the 4th quarter worth about $41,000. Renaissance Technologies LLC increased its holdings in Oncology Institute by 7.1% in the 4th quarter. Renaissance Technologies LLC now owns 182,000 shares of the company’s stock worth $56,000 after acquiring an additional 12,000 shares during the last quarter. Finally, FreeGulliver LLC increased its holdings in Oncology Institute by 219.3% in the 4th quarter. FreeGulliver LLC now owns 600,747 shares of the company’s stock worth $186,000 after acquiring an additional 412,578 shares during the last quarter. Hedge funds and other institutional investors own 36.86% of the company’s stock.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.